This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00209805%3A_____%2F09%3A%230000109%21RIV10-MZ0-00209805/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/domain/vavai/projekt/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n8http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00209805%3A_____%2F09%3A%230000109%21RIV10-MZ0-00209805
rdf:type
n8:Vysledek skos:Concept
dcterms:description
Trastuzumab, a humanized monoclonal antibody against the HER-2 receptor, was the first targeted therapy for HER-2 positive breast cancer. The treatment of HER-2 positive breast cancer in monotherapy, but mainly in combination with cytostatics trastuzumab, showed significant efficacy and increased the time to progression/relapse and overall survival. On the other hand, despite it being administered to only a selected patient population, the response rate varies in range and duration due to the primary or acquired tumor resistance to trastuzumab. Several mechanisms contributing to the drug resistance are presumed and overcoming strategies are in development. In connection with the drug resistance there are the mechanisms of trastuzumab's action on tumor cells and the search for feasible biomarkers in order to predict the response of trastuzumab-based targeted therapies. Furthermore, we present here the actual possibilities to overcome primary or acquired trastuzumab resistance. Trastuzumab, humanizovaná monoklonálna protilátka proti HER-2 receptoru, bol prvou cielenou liečbou pre pacientky s HER-2 pozitívnym karcinómom prsnika. Samostatne, ale hlavne v kombinácii s chemoterapiou trastuzumab zvyšuje liečebnú odpoveď, predlžuje čas do progresie/relapsu ochorenia i celkové prežitie pacientok. Na strane druhej, i napriek tomu, že je trastuzumab podávaný úzkej vyselektovanej skupine pacientok, odpoveď na túto cielenú liečbu je variabilná, a to ako v rozsahu, tak i v dĺžke trvania. Príčinou je existencia primárnej a prípadne vznik sekundárnej rezistencie ochorenia voči tejto protilátke. Predpokladá sa existencia niekoľkých možných mechanizmov rezistencie a vyvíjajú sa stratégie na ich prekonanie. S tým úzko súvisia mechanizmy posobenia trastuzumabu na nádorovú bunku a možnosti predikcie odpovedi na túto liečbu.V článku ďalej poukážeme na aktuálne možnosti prekonania primárnej a indukovanej rezistencie k trastuzumabu.
dcterms:title
Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms Trastuzumab v liečbe karcinómu prsníka: mechanizmy účinku a rezistencie
skos:prefLabel
Trastuzumab v liečbe karcinómu prsníka: mechanizmy účinku a rezistencie Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms
skos:notation
RIV/00209805:_____/09:#0000109!RIV10-MZ0-00209805
n3:aktivita
n12:P
n3:aktivity
P(NR8335)
n3:cisloPeriodika
2
n3:dodaniDat
n4:2010
n3:domaciTvurceVysledku
n6:2912589 n6:7947429 n6:6760074 n6:4447476 n6:8836299
n3:druhVysledku
n14:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n9:predkladatel
n3:idSjednocenehoVysledku
346846
n3:idVysledku
RIV/00209805:_____/09:#0000109
n3:jazykVysledku
n10:sla
n3:klicovaSlova
Trastuzumab, breast cancer, oncogene protein HER-2, mechanism of action, drug resistance
n3:klicoveSlovo
n15:mechanism%20of%20action n15:breast%20cancer n15:oncogene%20protein%20HER-2 n15:drug%20resistance n15:Trastuzumab
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[4FC1B7BC1202]
n3:nazevZdroje
Klinická onkologie
n3:obor
n11:FD
n3:pocetDomacichTvurcuVysledku
5
n3:pocetTvurcuVysledku
5
n3:projekt
n16:NR8335
n3:rokUplatneniVysledku
n4:2009
n3:svazekPeriodika
22
n3:tvurceVysledku
Svoboda, Marek Šimíčková, Marta Fabian, Pavel Grell, Peter Vyzula, Rostislav
s:issn
0862-495X
s:numberOfPages
7